Grateful to be working towards creating safe, effective and efficient treatments for LPR, addressing a significant unmet clinical need.

I’d like to congratulate my co-founder and friend on this honourable achievement. I believe this prestigious award is a testament to her groundbreaking work. Dr. Johnston’s research is poised to make critical therapeutic impacts in the area of reflux and related diseases.

N-Zyme would like to congratulate Simon Blaine-Sauer and team on their recent paper ‘The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes’ that was just published in the

N-Zyme is pleased to announce that its co-founders, Dr. Nikki Johnston and Franco Vigile, filed a patent on March 27th, 2024, for ‘Methods and compositions for treatment of peptic ulcers and/or peptic ulcer disease’ (Provisional application # 63/569,875). This patent filing

Modern diagnostic technologies have revealed why a significant percentage of people experience little to no relief with currently available treatment options for reflux and our mission is to address this critical unmet need in clinical care.

An excellent discussion with N-Zyme’s co-founder and Chief Scientific Officer, Dr. Nikki Johnston on the impact of LPR and GERD on millions of individuals and the groundbreaking, transformative efforts we are undertaking at N-Zyme to meet this significantly unmet clinical need.

Thanks to John Mercure and Julia Fello at 620 WTMJ for the opportunity to discuss our new drug for reflux. To view video: youtube.com/watch?v=QiO_r4…

Welcome to the team, Brendan Hussey, Ph.D! We’re looking forward to continuing to work together to revolutionize the reflux industry and address a significantly unmet clinical need.

N-Zyme is pleased to announce that, in addition to its transition to a Delaware corporation earlier this year, the Company has established a new corporate headquarters located at 1225 Discovery Parkway, Suite 260E, Wauwatosa, WI 53266.